Lipoprotein aferezi homozigot ailevi hiperkolesterolemi hastalarında ventriküler repolarizasyonu etkiler

Abstract

Amaç: Homozigot ailevi hiperkolesterolemisi (HoAH) olan hastalar erken yaşlarda kardiyovasküler hastalığa yakalanma riski altındadırlar ve genellikle genç yaşta ani kardiyak ölüm (SCD) nedeniyle kaybedilirler. Bu hastalarda ömrü uzatmak amacı ile tercih edilen tedavi yöntemi lipoprotein aferezidir (LA). LA’nın kısa ve uzun dönem klinik faydalarından açıklamak için çeşitli mekanizmalar önerilmiştir. Bu çalışmada, HoAH’si olan hastalarda tek seans LA'nın, ventriküler repolarizasyon parametreleri üzerine olan etkisini araştırdık.

Gereç ve Yöntemler: LA uygulanan 11 HoAH hastası çalışmaya dahil edildi. Hastaların ortalama yaşı 30.1 ± 5,5 yıl ve hastaların %63,6’sı erkek idi. Tüm hastalara double filtrasyon plazmaferez uygulandı.  İşlem öncesi ve sonrasında hastaların ventriküler repolarizasyon parametrelerinden OT, QTc aralığı, Tp-e aralığı, Tp-e / QT ve Tp-e / QTc oranı incelendi.

Bulgular: Tek seans lipoprotein aferezi LDL'yi anlamlı bir şekilde düşürdü (10.04 ± 1.91'den 4.16 ± 1.21 mmol / L, P <001). İşlem sonrası plazma kalsiyum ve magnezyum seviyeleri anlamlı derecede azaldı. QTc 443.8 ± 23.3 ms'den 412.3 ± 20.0 ms'ye (P <0.001) düştüğü saptandı. Tp-e aralığı ve Tp-e / QTc oranları önemli ölçüde azaldı [85 (70-89) ms ile 63 (58-71) ms; P = 0.003 ve 0.19 (0.16-0.20) - 0.15 (0.13-0.16); P = 0,003,  sırasıyla].

Sonuç: Verilerimiz, tek bir lipoprotein aferez seansının bile elektrokardiyografik repolarizasyon indekslerini iyileştirdiğini göstermiştir.

Keywords

• Aferez,aritmi,çift filtrasyon plazmaferez,homozigot ailesel hiperlipidemi,repolarizasyon dispersiyonu

Lipoprotein apheresis affects ventricular repolarization in patients with homozygous familial hypercholesterolemia

Abstract

Aim:  Patients with Homozygous Familial Hypercholesterolemia (HoFH) prone to experience premature cardiovascular disease and often die from sudden cardiac death (SCD) at a young age. Lipoprotein apheresis (LA) is the treatment of choice to prolong survival. Several mechanisms has been suggested to be responsible for the known short and long-term clinical benefits of this procedure. This study was conducted to assess the effect of single LA on ventricular repolarization parameters in patients with HoFH.

Material and Methods: Eleven patients (mean age 30.1 ± 5.5 years, male 63.6%) with HoFH on chronic LA treatment were enrolled in this preliminary study. Double filtration plasmapheresis (DFPP) was performed in all patients. To examine the effects of a single session of LA, on ventricular repolarization, the OT, QTc interval, the T peak-to-end (Tp-e) interval, Tp-e/QT and the Tp-e/QTc ratio were specifically calculated.

Results: The single session of LA reduced total LDL (from 10.04 ± 1.91 to 4.16 ± 1.21 mmol/L, P<001). The heart rate did not change significantly after LA session. Plasma levels of calcium and magnesium was significantly decreased after the procedure. The QTc decreased from 443.8 ± 23.3 ms to 412.3 ± 20.0 ms (P <0.001). The Tp-e interval and the Tp-e/QTc ratio decreased significantly [85 (70-89) ms vs. 63 (58-71)ms; P =0.003, and 0.19 (0.16-0.20) vs 0.15 (0.13-0.16); P =0.003, respectively].

Conclusion: Our data suggest that even a single session of LA improved electrocardiographic repolarization indexes.

Keywords

• apheresis,arrhythmia,dispersion of repolarization,double filtration plasmapheresis,homozygous familial hypercholesterolemia

References

1. 1. Cuchel M, Bruckert E, Ginsberg HN et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. European Heart Journal 2014; 35: 2146-57.
2. 2. Goldberg AC, Hopkins PN, Toth PP et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology 2011; 5:133-40.
3. 3. Julius U, Frind A, Tselmin S, Kopprasch S, Poberschin I, Siegert G. Comparison of different LDL apheresis methods. Expert Review of Cardiovascular Therapy 2008; 6: 629-39.
4. 4. Thompsen J, Thompson PD. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 2006; 189: 31-38.
5. 5. Kopprasch S, Graessler J, Bornstein SR et al. Beyond lowering circulating LDL: apheresis-induced changes of systemic oxidative stress markers by four different techniques. Atherosclerosis Supplements 2009; 10: 34-38.
6. 6. Kopprasch S, Julius U, Gromeier S, Kuhne H, Graessler J. Distinct effects of LDL apheresis by hemoperfusion (DALI) and heparin-induced extracorporeal precipitation (HELP) on leukocyte respiratory burst activity of patients with familial hypercholesterolemia. Journal of Clinical Apheresis 2000; 15: 249-55.
7. 7. Ramunni A, Burzo M, Verno L, Brescia P. Pleiotropic effects of LDL apheresis. Atherosclerosis Supplements 2009; 10: 53-55.
8. 8. Reimann M, Julius U, Haink K et al. LDL apheresis improves deranged cardiovagal modulation in hypercholesterolemic patients. Atherosclerosis 2010; 213: 212-17.

9. 9. Antzelevitch C. T peak-Tend interval as an index of transmural dispersion of repolarization. European Journal of Clinical Investigation. 2001; 31: 555-57.
10. 10. Antzelevitch C. Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes. American Journal of Physiology Heart and Circulatory 2007; 293: 2024-38
11. 11. Kroon AA, van't Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis. 2000; 152: 519-26.
12. 12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972; 18: 499-502.
13. 13. Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 1998; 98: 1928-36.
14. 14. Watanabe N, Kobayashi Y, Tanno K et al. Transmural dispersion of repolarization and ventricular tachyarrhythmias. Journal of Electrocardiology 2004; 37: 191-200.
15. 15. Wang Y, Lammi-Keefe CJ, Hou L, Hu G. Impact of low-density lipoprotein cholesterol on cardiovascular outcomes in people with type 2 diabetes: a meta-analysis of prospective cohort studies. Diabetes Research and Clinical Practice. 2013; 102: 65-75.
16. 16. Mabuchi H, Koizumi J, Shimizu M et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. The American Journal of Cardiology. 1998; 82: 1489-95.
17. 17. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95: 76-82.
18. 18. Igarashi K, Tsuji M, Nishimura M, Horimoto M. Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia. Journal of Clinical Apheresis 2004; 19: 11-16.
19. 19. Mellwig KP, Baller D, Gleichmann U et al. Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis. 1998; 139: 173-78.
20. 20. Chiu HC, Kovacs A, Blanton R et al. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circulation Research. 2005; 96: 225-33.
21. 21. Park TS, Hu Y, Noh HL et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. Journal of Lipid Research 2008; 49: 2101-12.
22. 22. Lin LC, Wu CC, Yeh HI et al. Downregulated myocardial connexin 43 and suppressed contractility in rabbits subjected to a cholesterol-enriched diet. Lab Invest 2005; 85: 1224-37.
23. 23. Meenagh C, Mulholland C, Ryan MF. Magnesium homeostasis and antipsychotic-induced QTc prolongation. Journal of Psychopharmacology 2004; 18: 438-39.
24. 24. Vemuri R, Philipson KD. Influence of sterols and phospholipids on sarcolemmal and sarcoplasmic reticular cation transporters. The Journal of biological chemistry. 1989; 264: 8680-85.
25. 25. Ortega A, Mas-Oliva J. Cholesterol effect on enzyme activity of the sarcolemmal (Ca2+ + Mg2+)-ATPase from cardiac muscle. Biochimica et Biophysica Acta. 1984; 773: 231-36.
26. 26. Moffat MP, Dhalla NS. Heart sarcolemmal ATPase and calcium binding activities in rats fed a high cholesterol diet. The Canadian Journal of Cardiology. 1985; 1: 194-200.
27. 27. Chen CC, Lin YC, Chen SA et al. Shortening of cardiac action potentials in endotoxic shock in guinea pigs is caused by an increase in nitric oxide activity and activation of the adenosine triphosphate-sensitive potassium channel. Critical Care Medicine 2000; 28: 1713-20.
28. 28. Kulmatycki KM, Abouchehade K, Sattari S, Jamali F. Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat. British Journal of Pharmacology 2001; 133: 286-94.